Novavax (NVAX) Competitors $8.85 -0.02 (-0.27%) As of 01:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVAX vs. MRNA, OCGN, VXRT, JNJ, PFE, ALKS, LGND, FOLD, MNKD, and CLDXShould you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Moderna (MRNA), Ocugen (OCGN), Vaxart (VXRT), Johnson & Johnson (JNJ), Pfizer (PFE), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), MannKind (MNKD), and Celldex Therapeutics (CLDX). These companies are all part of the "medical" sector. Novavax vs. Its Competitors Moderna Ocugen Vaxart Johnson & Johnson Pfizer Alkermes Ligand Pharmaceuticals Amicus Therapeutics MannKind Celldex Therapeutics Novavax (NASDAQ:NVAX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability. Does the media prefer NVAX or MRNA? In the previous week, Moderna had 13 more articles in the media than Novavax. MarketBeat recorded 20 mentions for Moderna and 7 mentions for Novavax. Moderna's average media sentiment score of 0.57 beat Novavax's score of 0.47 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 8 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive Is NVAX or MRNA more profitable? Novavax has a net margin of 39.20% compared to Moderna's net margin of -94.31%. Moderna's return on equity of -25.96% beat Novavax's return on equity.Company Net Margins Return on Equity Return on Assets Novavax39.20% -142.33% 28.65% Moderna -94.31%-25.96%-20.09% Which has more volatility & risk, NVAX or MRNA? Novavax has a beta of 2.68, indicating that its share price is 168% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Do institutionals and insiders have more ownership in NVAX or MRNA? 53.0% of Novavax shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 1.0% of Novavax shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher earnings & valuation, NVAX or MRNA? Novavax has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovavax$682.16M2.12-$187.50M$2.283.91Moderna$3.24B3.21-$3.56B-$7.53-3.55 Do analysts rate NVAX or MRNA? Novavax presently has a consensus price target of $14.29, suggesting a potential upside of 60.24%. Moderna has a consensus price target of $41.81, suggesting a potential upside of 56.62%. Given Novavax's stronger consensus rating and higher probable upside, equities research analysts clearly believe Novavax is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novavax 3 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.13Moderna 4 Sell rating(s) 14 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.05 SummaryNovavax beats Moderna on 9 of the 17 factors compared between the two stocks. Get Novavax News Delivered to You Automatically Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVAX vs. The Competition Export to ExcelMetricNovavaxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.45B$3.15B$5.76B$10.50BDividend YieldN/A2.36%5.61%4.58%P/E Ratio3.9321.0376.6326.90Price / Sales2.12451.34551.24127.98Price / CashN/A44.8325.8131.15Price / Book-2.299.8413.666.52Net Income-$187.50M-$52.73M$3.29B$271.58M7 Day Performance4.15%3.65%2.40%3.67%1 Month Performance13.71%5.95%4.81%8.14%1 Year Performance-30.35%17.38%81.05%26.94% Novavax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVAXNovavax4.2363 of 5 stars$8.89+0.2%$14.29+60.7%-31.3%$1.44B$682.16M3.901,990MRNAModerna4.4691 of 5 stars$23.88+1.6%$41.81+75.1%-59.6%$9.29B$3.24B-3.175,800OCGNOcugen1.4649 of 5 stars$1.20+12.1%$6.00+400.0%+25.2%$350.76M$4.05M-6.0080Analyst UpgradeHigh Trading VolumeVXRTVaxart2.0058 of 5 stars$0.37-6.0%$2.00+445.6%-54.1%$83.93M$47.40M-1.36120Gap DownJNJJohnson & Johnson4.7593 of 5 stars$177.49-0.3%$176.29-0.7%+6.1%$427.46B$90.63B18.98138,100Trending NewsAnalyst UpgradePFEPfizer4.9852 of 5 stars$23.98+0.5%$28.12+17.3%-18.3%$136.34B$63.63B12.7681,000Trending NewsAnalyst UpgradeOptions VolumeALKSAlkermes4.6515 of 5 stars$26.52-1.7%$41.85+57.8%-3.2%$4.38B$1.51B12.751,800Positive NewsLGNDLigand Pharmaceuticals4.053 of 5 stars$165.52-0.1%$176.50+6.6%+66.1%$3.24B$187.58M-41.3880Positive NewsFOLDAmicus Therapeutics3.947 of 5 stars$7.73-3.3%$16.00+107.0%-24.1%$2.38B$571.16M-64.41480Analyst UpgradeMNKDMannKind4.3021 of 5 stars$5.38-3.4%$11.17+107.6%-15.6%$1.65B$301.74M48.91400High Trading VolumeCLDXCelldex Therapeutics1.8197 of 5 stars$24.50+0.2%$46.67+90.5%-39.7%$1.63B$7.02M-8.14150 Related Companies and Tools Related Companies Moderna Alternatives Ocugen Alternatives Vaxart Alternatives Johnson & Johnson Alternatives Pfizer Alternatives Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives MannKind Alternatives Celldex Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVAX) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVAX Stock Alerts